Isavuconazonium

Contraindicated

Isavuconazonium Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Isavuconazonium Ketoconazole Topical Extina® Foam Increased isavuconazole (active form of isavuconazonium sulfate) exposure Details

Major

Isavuconazonium Relugolix Orgovyx Explained Increased relugolix exposure Details Isavuconazonium Atogepant Qulipta Reduced atogepant exposure Details Isavuconazonium Avapritinib Ayvakit Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Isavuconazonium Atorvastatin Atorvaliq Increased atorvastatin exposure Details Isavuconazonium Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Isavuconazonium Amlodipine Amvaz® Increased amLODIPine exposure, an increased risk of hypotension and edema and reduced amLODIPine exposure Details Isavuconazonium Bedaquiline Sirturo Increased bedaquiline exposure Details Isavuconazonium Brexpiprazole Rexulti Increased brexpiprazole exposure Details Isavuconazonium Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Isavuconazonium Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Isavuconazonium Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Isavuconazonium Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Isavuconazonium Digoxin Cardoxin® Increased exposure of P-gp substrate Details Isavuconazonium Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Isavuconazonium Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Isavuconazonium Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Isavuconazonium Enasidenib Idhifa Reduced antifungal exposure and reduced efficacy of antifungal agent Details Isavuconazonium Encorafenib Braftovi Increased encorafenib exposure and an increased risk of encorafenib-related adverse events; reduced CYP3A4 substrate exposure and... Details Isavuconazonium Everolimus Afinitor Increased everolimus exposure Details Isavuconazonium Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Isavuconazonium Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions and increased isavuconazonium exposure a... Details Isavuconazonium Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Isavuconazonium Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Isavuconazonium Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Isavuconazonium Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Isavuconazonium Lumateperone Caplyta Altered (reduced/increased) lumateperone exposure and an increased risk of lumateperone-related adverse reaction Details Isavuconazonium Lurbinectedin Injection Zepzelca Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Isavuconazonium Metformin Fortamet® Increased metFORMIN exposure and an increased risk of lactic acidosis Details Isavuconazonium Methylergonovine Methergine Increased methylergonovine exposure and an increased risk of vasospasm, cerebral ischemia and/or ischemia of extremities Details Isavuconazonium Midazolam Nasal Spray Nayzilam Increased midazolam exposure Details Isavuconazonium Midazolam Injection Nayzilam Increased midazolam exposure Details Isavuconazonium Mitapivat Aqvesme Increased mitapivat exposure and reduced CYP3A4 substrate exposure Details Isavuconazonium Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Isavuconazonium Nifedipine Adalat® Increased NIFEdipine exposure and reduced NIFEdipine exposure Details

Moderate

Isavuconazonium Dofetilide Tikosyn Increased dofetilide exposure Details Isavuconazonium Hydrocortisone Ala-Cort Altered (increased/reduced) hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Isavuconazonium Hydrocortisone Injection A-Hydrocort® Altered (increased/reduced) hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details